The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus.
Mice infected with live vesicular stomatitis virus (VSV) produced primary antibody responses more efficiently (with doses greater than 10(2) pfu) than those injected with UV-inactivated VSV (greater than 10(6) pfu) or purified VSV glycoprotein G (equivalent to 10(7) pfu) by producing neutralizing antibodies. Very low doses of live VSV (less than 10(2) pfu) failed to prime mice. Normal mouse serum had the capacity to inactivate VSV by heat-labile and immunoglobulin-mediated mechanisms in vitro independently of specifically induced antibodies. Studies using B cell-depleted agammaglobulinaemic mice showed that their serum lacked VSV-neutralizing capacity in vitro and that naturally resistant mice became susceptible to VSV-induced paralytic disease which could be prevented by adoptive transfer of immune but also of normal serum.
Gobet
R
R
Department for Experimental Pathology, University Hospital, Zürich, Switzerland.
Cerny
A
A
Rüedi
E
E
Hengartner
H
H
Zinkernagel
R M
RM
D000818:Animals; D000914:Antibodies, Viral / Q000502:physiology*; D005260:Female; D006801:Humans; D007106:Immune Sera; D007113:Immunity, Innate; D007074:Immunoglobulin G / Q000502:physiology; D008562:Membrane Glycoproteins; D051379:Mice; D008815:Mice, Inbred Strains; D009500:Neutralization Tests; D015164:Vaccines, Inactivated / Q000276:immunology; D014721:Vesicular stomatitis Indiana virus / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; C028391:G protein, vesicular stomatitis virus; D007106:Immune Sera; D007074:Immunoglobulin G; D008562:Membrane Glycoproteins; D015164:Vaccines, Inactivated; D014759:Viral Envelope Proteins; D014765:Viral Vaccines